Abstracts tagged "race/ethnicity"

Abstract Number: 0993 • ACR Convergence 2024
Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis
Muhammad Naveed¹, Rabia Iqbal¹, Kishan Patel², Ahila Ali¹, Simran Bhimani³, Bazil Azeem⁴, Yash Deshpande³, Muhammad Omer Rehan¹, Faizan Ahmed⁵, Hussain Haider Shah¹ and Nouman Shafique⁶, ¹Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, ²Riverside Community Hospital, Riverside, CA, ³The Wright Center for graduate medical education, Scranton, PA, ⁴Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, ⁵Ameer-ud-Din Medical College, Lahore, Pakistan, ⁶AdventHealth Orlando, Orlando, FL
Background/Purpose: Pulmonary complications in rheumatoid arthritis (RA) are an important cause of mortality among older adults. This study analyzes trends and demographic disparities in mortality…
Abstract Number: 1920 • ACR Convergence 2024
Admixture Mapping and Gene-Based Analysis Identifies Rare Variants in Genes in the IL-13 and TGFβ Signaling Pathways in African Americans with Systemic Sclerosis
Jordan Hicks¹, Daniel Shriner², Ami Shah³, Maureen Mayes⁴, Ayo P. Doumatey², Amy R. Bentley¹, Robyn Domsic⁵, Thomas Medsger, Jr⁶, Paula Ramos⁷, Richard Silver⁸, Virginia Steen⁹, John Varga¹⁰, Vivien Hsu¹¹, Lesley Ann Saketkoo¹², Dinesh Khanna¹⁰, Elena Schiopu¹³, Jessica Gordon¹⁴, Lindsey Criswell¹⁵, Heather Gladue¹⁶, Chris Derk¹⁷, Elana Bernstein¹⁸, S. Louis Bridges¹⁴, Victoria Shanmugam¹⁹, Lorinda Chung²⁰, Suzanne Kafaja²¹, Reem Jan²², Marcin Trojanowski²³, Avram Goldberg²⁴, Benjamin Korman²⁵, James W. Thomas²⁶, Elaine Remmers²⁷, Adebowale Adeyemo², Charles Rotimi², Fredrick Wigley²⁸, Francesco Boin²⁹, Daniel Kastner³⁰ and Pravitt Gourh³¹, ¹National institute of Health, Bethesda, MD, ²Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ⁷Medical University of South Carolina, Charleston, SC, ⁸Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁹Georgetown University School of Medicine, Washington, DC, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, ¹²New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ¹³Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, ¹⁴Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁵Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹⁶Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ¹⁹NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²⁰Stanford University, Woodside, CA, ²¹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²²Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, ²³Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²⁴NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁵University of Rochester, Rochester, NY, ²⁶NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²⁷Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²⁸Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ²⁹Cedars-Sinai Medical Center, Los Angeles, CA, ³⁰National Human Genome Research Institute, Bethesda, MD, ³¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD
Background/Purpose: There are significant racial disparities in systemic sclerosis (SSc), with an increased disease burden and worse outcomes among African American (AA) individuals. Reasons for…
Abstract Number: 0174 • ACR Convergence 2024
A Nationwide Analysis of Gender and Racial Disparities in Patients with Systemic Sclerosis and Acute Coronary Syndrome
Omair Khan¹, Kundan Jana², Azka Naeem², Syed Mujtaba Baqir², Marlon Rivera Boadla², Muhammad Hashim khan² and Vijay Shetty², ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune condition characterized by widespread skin fibrosis and/or end-organ damage. Previous studies have reported variable outcomes of the disease…
Abstract Number: 1016 • ACR Convergence 2024
Pharmacoequity of DMARDs Among Adults with Rheumatoid Arthritis in the U.S
Ashkan Ara¹, Matthew Chenoweth², Srikanth Kadiyala², Utibe Essien³ and Christopher Scannell³, ¹Division of Rheumatology, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, ²Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, ³Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles
Background/Purpose: Long-term management of rheumatoid arthritis (RA) relies on disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic (csDMARDs), biologic (bDMARDs), and targeted synthetic (tsDMARDs). About 40%…
Abstract Number: 1921 • ACR Convergence 2024
Devastating Morbidity and Mortality Rates in the Hmong Population with a Diagnosis of Gout Who Had a COVID-19 Infection
Kari Falaas¹, Michael Schnaus², Margaret Singer³, Allison Hochstetler³, Pang Nhia Khang⁴, Katherine Schmiechen⁴ and Elie Gertner³, ¹University of Minnesota, Regions Hospital, Minneapolis, MN, ²University of Minnesota, Regions Hospital, Methodist Hospital, Minneapolis, ³University of Minnesota, Regions Hospital, Minneapolis, ⁴Regions Hospital, Minneapolis
Background/Purpose: Hyperuricemia is associated with an elevated risk of developing cardiovascular diseases, diabetes, chronic kidney disease, and metabolic syndromes. The Hmong population, in particular, has…
Abstract Number: 0176 • ACR Convergence 2024
Race-Based Differences in Immune Responses Following an Episode of Acute Low Back Pain Among Those Who Develop Chronic LBP and Those Who Do Not
Colleen Burke¹, Michael Brown², Rebecca Fillipo³, Stephanie Danyluk², Kelley Seebeck² and Adam Goode², ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University, Durham, NC, ³Duke University School of Medicine, Durham, NC
Background/Purpose: Acute low back pain (LBP) affects over 25% of adults annually in the United States, and as many as one-third of these individuals will…
Abstract Number: 1030 • ACR Convergence 2024
Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region
Mathieu Choufani¹, Wissam Ghusn² and Joerg Ermann³, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Department of Internal Medicine, Boston Medical Center, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: While axial spondyloarthritis (AxSpA) was historically perceived as a "white man's disease", it is now appreciated as a condition that can affect individuals of…
Abstract Number: 1924 • ACR Convergence 2024
Racial and Gender Disparities in Psoriatic Arthritis Clinical Trials
Dania Kaur¹, Fizza Zulfiqar², Akshee Batra³ and Abhinav Vyas⁴, ¹North Alabama Medical Center, Muscle Shoals, AL, ²Trinity Health Oakland/Wayne State University, Pontiac, MI, ³University of Miami, Miami, FL, ⁴Vanderbilt University Medical Center, Nahville, TN
Background/Purpose: To develop effective novel treatment strategies for psoriatic arthritis that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
Abstract Number: 0180 • ACR Convergence 2024
Collaborative Solutions to Lupus Trial Challenges for Underrepresented Participant Recruitment & Engagement: Perspectives from the Lupus Clinical Investigators Network (LuCIN)
Brandon Jackson¹, Maria Dall'Era², Saira Sheikh³, Xueting Zhang⁴, Taylor Irons⁵, Claire Finney⁶, Taylor Adjei⁷, Jennifer Meriwether⁷, Caroline Donovan⁸, Carla Menezes⁹ and Stacie Bell¹⁰, ¹Lupus Research Alliance / Lupus Therapeutics, Miami, FL, ²UCSF, Corte Madera, CA, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Weill Cornell, New York, NY, ⁵Lupus Research Alliance / Lupus Therapeutics, Houston, ⁶Lupus Research Alliance / Lupus Therapeutics, Birmingham, AL, ⁷Lupus Research Alliance / Lupus Therapeutics, New York, NY, ⁸Lupus Research Alliance / Lupus Therapeutics, Arlington, VA, ⁹Lupus Research Alliance / Lupus Therapeutics, Brooklyn, NY, ¹⁰Lupus Therapeutics, Lakewood, CO
Background/Purpose: Racial and ethnic minority groups face higher lupus prevalence and severity and remain inadequately represented in lupus clinical trials. Lupus Therapeutics, the clinical affiliate…
Abstract Number: 1033 • ACR Convergence 2024
Osteoporosis and Cardiovascular Disease: Mortality Trends Among Adults in the United States from 1999 to 2020
Muhammad Naveed¹, Farman Ali², Ahila Ali¹, Bazil Azeem³, Faizan Ahmed⁴, Rabia Iqbal¹, Muhammad Omer Rehan¹, Nouman Shafique⁵, Syed Ishaq⁶, Aman Ullah⁷ and Sherif Eltawansy⁸, ¹Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan, ²Corewell Health, Dearborn Hospital, Dearborn, MI, Dearborn, MI, ³Shaheed Mohtarma Benazir Bhutto Medical College Liyari, Karachi, Pakistan, ⁴Ameer-ud-Din Medical College, Lahore, Pakistan, ⁵AdventHealth Orlando, Orlando, FL, ⁶Sinai Hospital of Baltimore, Baltimore, MD, ⁷SSM Health St Louis University Hospital, St. Louis, MO, ⁸Jersey Shore University Medical Centre, Neptune, NJ
Background/Purpose: Osteoporosis and cardiovascular disease (CVD) represent significant public health concerns. This study investigates the trends and demographic disparities in mortality due to osteoporosis and…
Abstract Number: 2313 • ACR Convergence 2024
Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis
Christine Loftis¹, Liron Caplan², Joanna Padilla Zepeda³, Nicole Mukooba³, Mayan Caplan³, Meika Fang⁴, Liya Stolyar⁵, Jessica Walsh⁶, Gail Kerr⁷, Siba Raychaudhuri⁸, Andreas Reimold⁹ and Maida Wong¹⁰, ¹University of Colorado Anschutz School of Medicine, Aurora, CO, ²Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ³University of Colorado, Aurora, CO, ⁴Veterans Affairs, Los Angeles, ⁵Veterans Affairs, Palo Alto, ⁶Veterans Affairs, Salt Lake City, UT, ⁷Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁸Veterans Affairs, Sacramento, ⁹University of Texas Southwestern Medical School, Dallas, ¹⁰Veterans Affairs, Long Beach
Background/Purpose: Studies have suggested a delay between symptom onset and diagnosis for Psoriatic Arthritis (PsA) and axial spondyloarthritis (axSpA). Factors that influence this delay have…
Abstract Number: 0183 • ACR Convergence 2024
Sensitivity of 2019 EULAR/ACR SLE Criteria and Initial Organ Manifestations for Black and Hispanic Children with Juvenile Systemic Lupus Erythematosus (jSLE) at a Large Tertiary Care Center
Michelle Butts¹, Emily Beil¹, Danielle Guffey², Andrea Ramirez¹, Cagri Yildirim-Toruner³, Erin Peckham-Gregory¹ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disorder with diverse features, posing classification challenges. In 2019, EULAR and ACR developed new classification criteria to…
Abstract Number: 1073 • ACR Convergence 2024
Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting
Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…
Abstract Number: 2388 • ACR Convergence 2024
Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
Katrina Williamson¹, Herbert Heien², Maria Stevens², Cynthia Crowson², Rozalina McCoy² and Ali Duarte-Garcia², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have been shown to have increased burden of multimorbidity. Racial disparities in multimorbidity have also been shown repeatedly.…
Abstract Number: 0711 • ACR Convergence 2023
IgA Vasculitis in a Diverse Adult Patient Population
Michelle Toker¹, Urmi Khanna¹, Roya Nazarian¹, Adhya Mehta², Bibi Ayesha¹, Anand Kumthekar¹ and Benedict Wu¹, ¹Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, ²Jacobi Medical Center, Bronx, NY
Background/Purpose: Immunoglobulin-A (IgA) Vasculitis (IgAV) is a small-vessel vasculitis that is primarily diagnosed based on the European League Against Rheumatism (EULAR) criteria. There is limited…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.